Management 2018-11-22T12:51:25+00:00
Nadav Kidron
Nadav Kidron, Esq
Chief Executive Officer, President & Director

Mr. Kidron serves as Chief Executive Officer & Director of Oramed Pharmaceuticals, which he co-founded in 2006.

Mr. Kidron is an entrepreneur whose experience includes senior executive roles in a wide range of industries.

He co-founded Entera Bio as a joint venture formed by Oramed and DNA Biomedical Solutions. He is a member of the IATI Board, and an international lecturer on Israel’s entrepreneurial culture and the country’s roots as an oasis of innovative ideas.

He holds a bachelor’s degree in law and an international master’s in business administration, both from Bar-Ilan University in Israel. Mr. Kidron is a fellow of the Merage Business Executive Leadership Program and a member of the Israeli Bar Association.

Miriam Kidron, Ph.D
Chief Scientific Officer & Director

Dr. Kidron serves as Chief Scientific Officer and Director of Oramed Pharmaceuticals, which she co-founded in 2006.

Dr. Kidron is a pharmacologist and biochemist, who earned her PhD in biochemistry from the Hebrew University of Jerusalem.

For close to 20 years, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah-Hebrew University Medical Center in Jerusalem, Israel, earning the Bern Schlanger Award for her work on diabetes research.

She was formerly a visiting professor at the Medical School at the University of Toronto and is a member of the American, European and Israeli Diabetes Associations.

Hilla Eisenberg, CPA
Chief Financial Officer

Ms. Eisenberg serves as Chief Financial Officer of Oramed Pharmaceuticals. She joined Oramed in 2016, and prior to her appointment as CFO served as the Company’s Finance Manager.

Prior to joining Oramed, she provided audit and accounting services at a certified public accounting firm in Israel and served as an auditor at PwC Israel (Kesselman & Kesselman) including a short secondment to PwC New York.

Ms. Eisenberg brings to Oramed very strong financial experience with an assortment of publicly traded and private companies.

Ms. Eisenberg holds a bachelor’s degree in accounting and economics from Tel-Aviv University and is a certified public accountant (CPA) in Israel.

Mark Hasleton, Ph.D, MBA
VP Business Development

Dr. Hasleton serves as Oramed’s Vice President of Business Development.

Mark has over 15 years  Pharma / Biotech experience including Medical, Marketing, R&D and Business Development.

Prior to joining the Oramed, Mark served in several leadership and pharmaceutical development roles. From 2010 to 2018, he served in Business Development and later as Senior Director of Portfolio – Global New Therapeutic Entities at Teva Pharmaceutical Industries Ltd. Prior to joining Teva, from 2007 to 2010, Mark was at Bristol Myers Squibb Co, in the UK and then in the European business as EMEA Business Operations Manager for MSLs in the region.

Mark has a PhD in molecular biology and cancer research from the Imperial College London, UK, a MRes in molecular biology from the University of Manchester, UK and an MBA from Tanaka Business School, Imperial College London, UK.